1. Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria. (1st July 2018) Authors: Curto‐Barredo, L.; Spertino, J.; Figueras‐Nart, I.; Expósito‐Serrano, V.; Guilabert, A.; Melé‐Ninot, G.; Cubiró, X.; Bonfill‐Ortí, M.; Garcias‐Ladaria, J.; Villar, M.; García‐Navarro, X.; Bielsa‐Marsol, I.; Vilavella, M.; Aparicio, G.; Baliu‐Piqué, C.; Álvarez, A.; Lamas‐Domenech, N.; Duran‐Jordà... Journal: British journal of dermatology Issue: Volume 179:Number 1(2018) Page Start: 210 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria. (25th April 2018) Authors: Curto‐Barredo, L.; Spertino, J.; Figueras‐Nart, I.; Expósito‐Serrano, V.; Guilabert, A.; Melé‐Ninot, G.; Cubiró, X.; Bonfill‐Ortí, M.; Garcias‐Ladaria, J.; Villar, M.; García‐Navarro, X.; Bielsa‐Marsol, I.; Vilavella, M.; Aparicio, G.; Baliu‐Piqué, C.; Álvarez, A.; Lamas‐Domenech, N.; Duran‐Jordà... Journal: British journal of dermatology Issue: Volume 179:Number 1(2018) Page Start: 210 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗